- Abzena has appointed Geoffrey M. Glass as Chief Executive Officer, effective immediately.
- Mr. Glass previously served as Chairman of the Board and has over 30 years of life sciences experience.
Abzena, an integrated CDMO and CRO specialising in complex biologics and bioconjugates, has announced the appointment of Geoffrey M. Glass as its new Chief Executive Officer, effective immediately. Mr. Glass has served as Chairman of the Board since 2022.
With three decades of experience in the life sciences sector, Mr. Glass has held leadership roles at EY Consulting, Valeant Pharmaceuticals (now Bausch Health), Patheon (now part of Thermo Fisher Scientific), Sancilio Pharmaceuticals, and KINICITI. He is also credited with playing a key role in building the CDMO sector over the past 15 years.
In a statement, Mr. Glass commented, “Over the past few years Abzena has made incredible progress driving operational execution and strengthening our unique scientific capabilities, the combination of which has resulted in delighting many of our customers.”
The Board of Directors expressed confidence in Mr. Glass’s ability to lead the organisation forward, noting his strategic leadership and deep operational expertise.
